BioSpace News Archive

Blacksmith Medicines, Inc. announced the company will present data on its oncology program targeting flap endonuclease 1, a structure-specific metallonuclease that cleaves 5' DNA flaps during replication and repair, at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10 at the San Diego Convention Center, San Diego CA.

Colossal Biosciences, the world’s first de-extinction company, announces that their Woolly Mammoth team has achieved a global-first iPSC breakthrough.

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor.

Phio Pharmaceuticals Corp. announced that the United States Patent and Trademark Office has granted patent application 17/150,614 for two of its INTASYL Compounds, RXI-185 and RXI-231.

The Allen Institute has officially become the newest member of the Weill Neurohub, a collaborative research network advancing treatments for neurological diseases.

ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented the oral abstract “Long-Acting Injectable CAB/RPV is Superior to Oral ART in PWH with Adherence Challenges: ACTG A5359” at the Conference on Retroviruses and Opportunistic Infections (CROI 2024), in Denver, Colorado.

Ryvu Therapeutics announced that on March 5, 2024 it has received formal confirmation of the fulfillment of the conditions necessary for the disbursement of the Tranche A of EUR 8 million venture debt from the European Investment Bank, under the financing agreement concluded on August 16, 2022.

Cognito Therapeutics, a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today the publication of the OVERTURE study results in Frontiers in Neurology.

The National Organization for Rare Disorders released its annual State Report Card, which grades each U.S. state on critical issues impacting access to care for the 1 in 10 Americans living with a rare disease.

MAIA Biotechnology, Inc. announced that Dr. Rachid Drissi, Principal Investigator at the Center for Childhood Cancer Research, Nationwide Children’s Hospital, and Associate Professor at Ohio State University, will present an abstract detailing the potency of THIO, MAIA’s telomere-targeting agent, as treatment for pediatric brain cancers at the American Association for Cancer Research Annual Meeting taking place April 5–10, 2024 in San Diego, California.